ArticleThe New England journal of medicine2020
A Trial of Lopinavir-Ritonavir in Covid-19.
Article in The New England journal of medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Difference of SARS-CoV-2 infection and influence factors between people with and without HIV infection.BMC public health · 2025Article
- Identification of Natural Compounds as Potential COVID-19 Main Protease (Mpro) Inhibitors: A Comprehensive Study andCurrent pharmaceutical design · 2025Review
- Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort.Frontiers in cellular and infection microbiology · 2024Article
- Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort.Frontiers in cellular and infection microbiology · 2024Article
- Comparative efficacy of repurposed drugs lopinavir-ritonavir and darunavir-ritonavir in hospitalised COVID-19 patients: insights from a tertiary centre cohort.Frontiers in cellular and infection microbiology · 2024Article
- Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2.MedComm · 2023Review
- Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy.European journal of hospital pharmacy : science and practice · 2022Article
- Flavonoids are promising safe therapy against COVID-19.Phytochemistry reviews : proceedings of the Phytochemical Society of Europe · 2022Review
- Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020.Caspian journal of internal medicine · 2022Article
- SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target.Cell research · 2021Article
- A scheme for inferring viral-host associations based on codon usage patterns identifies the most affected signaling pathways during COVID-19.Journal of biomedical informatics · 2021Article
- Article
- Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients.European journal of clinical pharmacology · 2021Article
- A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.PLoS biology · 2021Article
- A comprehensive review on potential therapeutics interventions for COVID-19.European journal of pharmacology · 2021Review
- Recent progress of antiviral therapy for coronavirus disease 2019.European journal of pharmacology · 2021Review
- Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.Drug design, development and therapy · 2021Review
- Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.Turkish journal of biology = Turk biyoloji dergisi · 2021Article
- Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor.Nucleosides, nucleotides & nucleic acids · 2021Review
- A severe COVID-19 despite ongoing treatment with Lopinavir-Ritonavir.Respiratory medicine and research · 2020Article
Corrections and comments
- Commented on by
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
32369281What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.